AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1200 participants.
Also called NCT07931573
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,200 participants
- Sponsor
- Registry
-
NCT07931573
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Brazil, Bulgaria, Canada, Croatia, Czechia, Denmark, Germany, Greece, Hungary, Israel, Italy, Poland, Portugal, Puerto Rico, Romania, Saudi Arabia, Slovakia, Spain, United Kingdom
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07931573. Randomized; quadruple masking; primary purpose treatment. Start 2026-11-10 (anticipated); primary completion 2028-07-04 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both
- Acronym
- AMBITION 3
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Zenagamtide
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct07931573- Content hash
cd5558c97ad2ba7918c5b2d5155aa34aa92e544055839a9e18bca6f5b44b9c44